GlassScriptPhysician profile
Evelyn Chavez
NPI 1023623519
$8,264.43
in general payments reported to CMS, 2019-2025
36 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $824 · 2022: $1,979 · 2023: $2,221 · 2024: $2,158 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,416 · Education: $45.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,416.42 |
| Education | $45.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,693.16 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,121.00 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $614.80 | 2021-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $553.93 | 2021-2025 | Entyvio |
| Intercept Pharmaceuticals, INC. | $492.63 | 2021-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $460.00 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $414.74 | 2021-2025 | |
| Celgene Corporation | $382.64 | 2022-2024 | Zeposia |
| Pfizer INC. | $244.88 | 2023-2025 | |
| Daiichi Sankyo INC. | $234.25 | 2021-2024 | Injectafer |
| Phathom Pharmaceuticals, INC. | $204.86 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $197.69 | 2022-2024 | Dificid, Zinplava |
| Nestle Healthcare Nutrition INC. | $161.63 | 2021-2023 | |
| Genzyme Corporation | $150.34 | 2023-2024 | |
| Ardelyx, INC. | $149.46 | 2023-2025 | Ibsrela |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $133.27 | 2024-2025 | Iqirvo, Bylvay |
| Ironwood Pharmaceuticals, INC | $130.03 | 2021-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $119.77 | 2023 | Zeposia |
| Lilly USA, LLC | $111.99 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $96.81 | 2023-2024 | |
| Braintree Laboratories, INC. | $82.05 | 2021-2025 | Suflave, Sutab |
| Fresenius Kabi USA, LLC | $78.56 | 2023-2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.28 | 2023 | Cyltezo |
| Madrigal Pharmaceuticals | $62.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $54.56 | 2024 | Vegzelma, Zymfentra |
| Alnylam Pharmaceuticals INC. | $34.28 | 2024-2025 | Givlaari |
| Sandoz INC. | $32.68 | 2024-2025 | Hyrimoz |
| Amgen INC. | $32.23 | 2022 | |
| Redhill Biopharma INC. | $29.07 | 2021 | |
| Mauna Kea Technologies, INC. | $21.53 | 2024 | |
| Ferring Pharmaceuticals INC. | $19.01 | 2023 | Rebyota |
| Astrazeneca Pharmaceuticals LP | $18.34 | 2022 | |
| Exact Sciences Corporation | $16.62 | 2024 | Cologuard Collection Kit |
| Ethicon US, LLC | $14.96 | 2022 | |
| Axonics, INC. | $14.05 | 2024 | Axonics |
| Endo Pharmaceuticals INC. | $13.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evelyn Chavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.